Stockscreener 앱 받기
1.6751
0.87%
-0.0149
전일 마감가:
$1.69
열려 있는:
$1.69
하루 거래량:
218.43K
Relative Volume:
0.32
시가총액:
$106.14M
수익:
$139.77M
순이익/손실:
$-97.62M
주가수익비율:
-1.0602
EPS:
-1.58
순현금흐름:
$-61.71M
1주 성능:
-4.81%
1개월 성능:
+5.36%
6개월 성능:
+29.87%
1년 성능:
-59.53%
1일 변동 폭
$1.635
$1.71
1주일 범위
$1.635
$1.83
52주 변동 폭
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
명칭
Macrogenics Inc
전화
301-251-5172
주소
9704 MEDICAL CENTER DRIVE, Rockville, MD
MGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.6792 | 106.82M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2024-11-07 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-05-10 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-04-26 | 개시 | B. Riley Securities | Buy |
| 2024-04-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-03-04 | 재확인 | BTIG Research | Buy |
| 2024-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-11-22 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-11-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-02-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-04 | 개시 | SMBC Nikko | Outperform |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-12 | 업그레이드 | Barclays | Underweight → Overweight |
| 2020-12-22 | 재개 | H.C. Wainwright | Buy |
| 2020-08-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-06-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2019-12-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-11-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Guggenheim | Neutral |
| 2019-02-07 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-02-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-02-06 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-12-10 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-05-31 | 개시 | Evercore ISI | Outperform |
| 2018-03-05 | 개시 | H.C. Wainwright | Buy |
| 2017-03-31 | 개시 | Raymond James | Outperform |
모두보기
Macrogenics Inc 주식(MGNX)의 최신 뉴스
Chart based analysis of MacroGenics Inc. trends2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Will MacroGenics Inc. stock rally after Fed decisions2025 Short Interest & Consistent Profit Alerts - newser.com
Can MacroGenics Inc. stock hit record highs againEarnings Overview Report & Long-Term Growth Portfolio Plans - newser.com
When is the best time to exit MacroGenics Inc.July 2025 Momentum & Low Risk High Reward Trade Ideas - newser.com
Applying Wyckoff theory to MacroGenics Inc. stock2025 Investor Takeaways & Daily Entry Point Trade Alerts - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for MacroGenics (NASDAQ:MGNX) - MarketBeat
Bispecific Antibodies MarketGlobal Forecast 2025-2032, Profiles of Key PlayersF. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab - Yahoo
Public Employees Retirement System of Ohio Has $31,000 Stake in MacroGenics, Inc. $MGNX - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
MacroGenics (NASDAQ:MGNX) and CeriBell (NASDAQ:CBLL) Head to Head Comparison - Defense World
Regression analysis insights on MacroGenics Inc. performanceDay Trade & Weekly Market Pulse Updates - newser.com
Using data models to predict MacroGenics Inc. stock movementJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Published on: 2025-10-05 06:01:39 - newser.com
Backtesting results for MacroGenics Inc. trading strategies2025 EndofYear Setup & Daily Risk Controlled Trade Plans - newser.com
Multi asset correlation models including MacroGenics Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
How currency fluctuations impact MacroGenics Inc. stockJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Developing predictive dashboards with MacroGenics Inc. dataWeekly Investment Report & Verified Entry Point Signals - newser.com
Published on: 2025-10-02 22:14:22 - newser.com
Voya Investment Management LLC Buys 40,500 Shares of MacroGenics, Inc. $MGNX - Defense World
Published on: 2025-09-30 05:12:41 - newser.com
What drives MacroGenics Inc stock priceCash Flow Trends & Amplify Gains With Picks - earlytimes.in
Goldman Sachs Group Inc. Has $251,000 Position in MacroGenics, Inc. $MGNX - MarketBeat
Extensive-Stage Small Cell Lung Cancer Pipeline 2025: Innovative Clinical Developments By 25+ Global Leaders Delveinsight Key Companies Featured Include Shanghai Henlius Biotech, Macrogenics, Inc. - Menafn.com
What drives PROG Holdings Inc AZD stock priceInterest Rate Changes & Small Capital Wealth Plans - earlytimes.in
*DJ Macrogenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA >MGNX - 富途牛牛
Strs Ohio Invests $263,000 in MacroGenics, Inc. $MGNX - MarketBeat
Intraday pattern recognizer results for MacroGenics Inc.July 2025 PostEarnings & Real-Time Volume Analysis - newser.com
Statistical indicators supporting MacroGenics Inc.’s strengthIPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Published on: 2025-09-22 05:42:18 - newser.com
Barclays Upgrades MacroGenics (NASDAQ:MGNX) to "Strong-Buy" - MarketBeat
MacroGenics (NASDAQ:MGNX) Now Covered by Analysts at Barclays - MarketBeat
Acadian Asset Management LLC Grows Position in MacroGenics, Inc. $MGNX - MarketBeat
Live market analysis of MacroGenics Inc.Quarterly Market Summary & Safe Capital Allocation Plans - newser.com
What institutional flow reveals about MacroGenics Inc.July 2025 Drop Watch & Capital Efficient Trade Techniques - newser.com
Momentum divergence signals in MacroGenics Inc. chartProfit Target & Weekly Market Pulse Alerts - newser.com
What indicators show strength in MacroGenics Inc.Weekly Investment Report & Free Growth Oriented Trading Recommendations - newser.com
Using economic indicators to assess MacroGenics Inc. potential2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
MacroGenics Inc. stock trend outlook and recovery pathDay Trade & Daily Technical Stock Forecast Reports - newser.com
Growth Recap: Will MacroGenics Inc outperform the market in YEARJuly 2025 Sentiment & Fast Entry High Yield Tips - خودرو بانک
Macrogenics Inc (MGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Macrogenics Inc 주식 (MGNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
| Bonvini Ezio | Sr VP, Research & CSO |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
124,414 |
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
1.10%
자본화:
|
볼륨(24시간):